Solid Tumors (IL-12) is under clinical development by Symvivo and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Solid Tumors (IL-12)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Solid Tumors (IL-12) overview
Gene therapy is under development for the treatment of refractory solid tumors. It is administered through intravenous route and acts by targeting interleukin 12 (IL-12). The drug candidate is a genetically modified Bifidobacterium longum (B longum), that is being developed based on bacTRL technology delivering IL-12 gene.
Symvivo is a biotechnology company which develops bacterial-based gene delivery platform for the treatment of solid tumors. The company’s bacTRL technology, administered as a single dose through intravenous injection, consists of a genetically modified probiotic bacteria that occupy primary and secondary solid tumor tissues, leaving out healthy tissues. It produces and delivers genetic material to the surrounding tumor microenvironment. Symvivo is also designing and delivering custom synthetic antigens, which facilitate the development of new and highly effective and safer technologies that eliminate dose limiting off-tumor side effects integral to existing immuno-oncology treatments. Symvivo is headquartered in Burnaby, British Columbia, Canada
For a complete picture of Solid Tumors (IL-12)’s drug-specific PTSR and LoA scores, buy the report here.